Hepatic Insufficiency/Liver Failure Market 2023: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast by 2033

IMARC Group has recently released a report titled “Hepatic Insufficiency/Liver Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033” that presents a comprehensive assessment of the hepatic insufficiency/liver failure market size, latest trends, and growth forecast. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the global market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.

Hepatic insufficiency, also known as liver failure, refers to a potentially fatal condition characterized by a severe deterioration in liver function. It is generally caused by liver abnormalities, which make it difficult or impossible for the liver to work. The early signs of this ailment are identical to any other liver illness, such as nausea, lack of appetite, exhaustion, bowel troubles, etc. However, when the condition advances, the symptoms may include fluid retention in the abdomen, vomiting containing blood due to blood vessel hemorrhage, gallstones, jaundice, loss of musculature, and kidney damage. Numerous tests, such as blood tests, CT scans, endoscopies, MRIs, ultrasounds, etc., are conducted to diagnose and treat liver failure.

Request a Free Sample Report: https://www.imarcgroup.com/hepatic-insufficiency-liver-failure-market/requestsample

Market Trend:

The growing cases of autoimmune illnesses and viral infections, like hepatitis, which may lead to significant liver damage, are primarily driving the hepatic insufficiency/liver failure market. Additionally, the increasing prevalence of several associated risk factors, such as excessive alcohol intake, high dosages of medications, including acetaminophen or paracetamol, advanced fatty liver condition, etc., is also contributing to the market growth. Besides this, the rising geriatric population, who are more prone to develop liver diseases, is acting as another significant growth-inducing factor. Additionally, ongoing biotechnological advancements, such as the launch of the bioartificial liver, which uses regenerated cells to replace liver functions, are positively impacting the market growth. Moreover, the growing awareness regarding liver diseases and the importance of early detection, and the increasing efforts of various leading manufacturers to improve liver transplant techniques are anticipated to propel the hepatic insufficiency/liver failure market.

Report Period:

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033

Countries Included:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the hepatic insufficiency/liver failure market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the hepatic insufficiency/liver failure market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status

Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/hepatic-insufficiency-liver-failure-market

Key Questions Answered in this Report:

  • How has the hepatic insufficiency/liver failure market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the hepatic insufficiency/liver failure market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the hepatic insufficiency/liver failure market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

About Us: –

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Hepatic Insufficiency/Liver Failure – Introduction
4.1 Overview
4.2 Epidemiology (2017-2022) and Forecast (2023-2033)
4.3 Market Overview (2017-2022) and Forecast (2023-2033)
4.4 Competitive Intelligence

5 Hepatic Insufficiency/Liver Failure – Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Hepatic Insufficiency/Liver Failure – Epidemiology and Patient Population
7.1 Epidemiology – Key Insights
7.2 Epidemiology Scenario – Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2022)
7.2.2 Epidemiology Forecast (2023-2033)
7.3 Epidemiology Scenario – United States
7.3.1 Epidemiology Scenario (2017-2022)
7.3.2 Epidemiology Forecast (2023-2033)
7.4 Epidemiology Scenario – Germany
7.4.1 Epidemiology Scenario (2017-2022)
7.4.2 Epidemiology Forecast (2023-2033)
7.5 Epidemiology Scenario – France
7.5.1 Epidemiology Scenario (2017-2022)
7.5.2 Epidemiology Forecast (2023-2033)
7.6 Epidemiology Scenario – United Kingdom
7.6.1 Epidemiology Scenario (2017-2022)
7.6.2 Epidemiology Forecast (2023-2033)
7.7 Epidemiology Scenario – Italy
7.7.1 Epidemiology Scenario (2017-2022)
7.7.2 Epidemiology Forecast (2023-2033)
7.8 Epidemiology Scenario – Spain
7.8.1 Epidemiology Scenario (2017-2022)
7.8.2 Epidemiology Forecast (2023-2033)
7.9 Epidemiology Scenario – Japan
7.9.1 Epidemiology Scenario (2017-2022)
7.9.2 Epidemiology Forecast (2023-2033)

8 Hepatic Insufficiency/Liver Failure – Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Hepatic Insufficiency/Liver Failure – Unmet Needs

10 Hepatic Insufficiency/Liver Failure – Key Endpoints of Treatment

11 Hepatic Insufficiency/Liver Failure – Marketed Products
11.1 List of Hepatic Insufficiency/Liver Failure Marketed Drugs Across the Top 7 Markets
11.1.1    Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the list of marketed drugs has been provided in the report.

12 Hepatic Insufficiency/Liver Failure – Pipeline Drugs
12.1 List of Hepatic Insufficiency/Liver Failure – Pipeline Drugs Across the Top 7 Markets
12.1.1 E3112 – EA Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2  Soticlestat – Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 F 573 – EpiCept Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Mesenchymal Stem Cell Therapy (HepaStem) – Cellaion
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Resatorvid – Akaza Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13. Hepatic Insufficiency/Liver Failure – Attribute Analysis of Key Marketed and Pipeline Drugs

14 Hepatic Insufficiency/Liver Failure – Market Scenario
14.1 Market Scenario – Key Insights
14.2 Market Scenario – Top 7 Markets
14.2.1    Hepatic Insufficiency/Liver Failure – Market Size
14.2.1.1 Market Size (2017-2022)
14.2.1.2 Market Forecast (2023-2033)
14.2.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2022)
14.2.2.2 Market Forecast by Therapies (2023-2033)
14.3 Market Scenario – United States
14.3.1    Hepatic Insufficiency/Liver Failure – Market Size
14.3.1.1 Market Size (2017-2022)
14.3.1.2 Market Forecast (2023-2033)
14.3.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2022)
14.3.2.2 Market Forecast by Therapies (2023-2033)
14.3.3    Hepatic Insufficiency/Liver Failure – Access and Reimbursement Overview
14.4 Market Scenario – Germany
14.4.1    Hepatic Insufficiency/Liver Failure – Market Size
14.4.1.1 Market Size (2017-2022)
14.4.1.2 Market Forecast (2023-2033)
14.4.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2022)
14.4.2.2 Market Forecast by Therapies (2023-2033)
14.4.3    Hepatic Insufficiency/Liver Failure – Access and Reimbursement Overview
14.5 Market Scenario – France
14.5.1    Hepatic Insufficiency/Liver Failure – Market Size
14.5.1.1 Market Size (2017-2022)
14.5.1.2 Market Forecast (2023-2033)
14.5.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2022)
14.5.2.2 Market Forecast by Therapies (2023-2033)
14.5.3    Hepatic Insufficiency/Liver Failure – Access and Reimbursement Overview
14.6 Market Scenario – United Kingdom
14.6.1    Hepatic Insufficiency/Liver Failure – Market Size
14.6.1.1 Market Size (2017-2022)
14.6.1.2 Market Forecast (2023-2033)
14.6.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2022)
14.6.2.2 Market Forecast by Therapies (2023-2033)
14.6.3    Hepatic Insufficiency/Liver Failure – Access and Reimbursement Overview
14.7 Market Scenario – Italy
14.7.1    Hepatic Insufficiency/Liver Failure – Market Size
14.7.1.1 Market Size (2017-2022)
14.7.1.2 Market Forecast (2023-2033)
14.7.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2022)
14.7.2.2 Market Forecast by Therapies (2023-2033)
14.7.3    Hepatic Insufficiency/Liver Failure- Access and Reimbursement Overview
14.8 Market Scenario – Spain
14.8.1    Hepatic Insufficiency/Liver Failure – Market Size
14.8.1.1 Market Size (2017-2022)
14.8.1.2 Market Forecast (2023-2033)
14.8.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2022)
14.8.2.2 Market Forecast by Therapies (2023-2033)
14.8.3    Hepatic Insufficiency/Liver Failure – Access and Reimbursement Overview
14.9   Market Scenario – Japan
14.9.1    Hepatic Insufficiency/Liver Failure – Market Size
14.9.1.1 Market Size (2017-2022)
14.9.1.2 Market Forecast (2023-2033)
14.9.2    Hepatic Insufficiency/Liver Failure – Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2022)
14.9.2.2 Market Forecast by Therapies (2023-2033)
14.9.3    Hepatic Insufficiency/Liver Failure – Access and Reimbursement Overview

15 Hepatic Insufficiency/Liver Failure – Recent Events and Inputs From Key Opinion Leaders

16 Hepatic Insufficiency/Liver Failure Market – SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix